SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma informs about receipt of establishment inspection report from US FDA

08 Nov 2023 Evaluate
Further to intimation dated July 28, 2023; Gland Pharma has informed that following the ‘Good Manufacturing Practice (GMP) Inspection’ by US FDA at the Company’s VSEZ Sterile Oncology Facility at Visakhapatnam between 20th July, 2023 and 28th July, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

The above information is a part of company’s filings submitted to BSE.

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×